Last Friday a U.S. Food & Drug Administration (FDA) advisory committee recommended (based on a 17 to 6 vote) that the labeling of bisphosphonates needed to be updated to make it clear how long patients should take these drugs to gain the greatest benefit and suffer the least risk. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: bisphosphonate, fracture, osteoporosis, Prevention, skeletal-related event | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 